Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOV-002 + carboplatin
- Development stage
- Unknown
- Lead developer
- Cellectar Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
NOV-002 + carboplatin is a combination therapy comprising **NOV-002**, a mimetic of oxidized glutathione (GSSG), and **carboplatin**, a DNA crosslinking platinum-based chemotherapeutic. NOV-002 modulates cellular redox balance through S-glutathionylation of proteins, impacting signaling pathways including AKT, JAK2, and STAT5, and acts as an immunostimulant and myeloproliferative agent. Carboplatin exerts cytotoxicity by DNA crosslinking and interfering with cell division. As a combination, this regimen was investigated for enhanced efficacy and tolerance of chemotherapy, particularly in advanced non–small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer. NOV-002 does not directly add to carboplatin's cytotoxicity but aims to improve hematologic recovery and reduce chemotherapy toxicity via redox modulation[1][2][3][4][5].
- Other names
- glutathione disulfide mimetic + carboplatin
02
Targets
DNAJAK2 (Janus kinase 2)Actin filament proteinsAKT (RAC-alpha serine/threonine-protein kinase)ERKP4HB (Protein disulfide-isomerase)RK (Ribokinase)GSR (Glutathione reductase)STAT5A (STAT5)JNK (Mitogen-activated protein kinase kinase kinase family)CSPT (Cell-surface protein thiol)
Beyond the preview
Go deeper on NOV-002 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOV-002 + carboplatin.